Oral Solid Dosage CDMO Market Size, Revenue, Trend Report 2026 to 2035
Market Segmentation:
Oral Solid Dosage CDMO Market by Service Type -
• Formulation Development
• Process Development and Scale-Up
• Clinical Trial Manufacturing (Phase I / II / III)
• Commercial Manufacturing
• Packaging, Serialization, and Labelling
• Analytical, Stability, and QC Services
• Regulatory and CMC Support
Oral Solid Dosage CDMO Market by Dosage Form -
• Immediate-Release Tablets
• Modified-Release Tablets (SR / CR / DR / ER / Pulsatile)
• Coated Tablets (Film, Sugar, Enteric)
• Hard Capsules (Gelatin and HPMC)
• Soft Gelatin Capsules
• Orally Disintegrating Tablets (ODT)
• Multiparticulates (Pellets, Beads, Mini-Tablets, MUPS)
• Granules, Sachets, and Stick Packs
• Powders for Oral Suspension
• Chewables, Lozenges, and Effervescent Tablets
Oral Solid Dosage CDMO Market by Manufacturing Technology -
• Wet Granulation
• Dry Granulation and Roller Compaction
• Direct Compression
• Hot Melt Extrusion
• Spray Drying
• Fluid Bed Processing and Coating
• Compression and Film Coating
• Encapsulation (Powder, Pellet, LFHC)
• Continuous Manufacturing
• 3D Printing
Oral Solid Dosage CDMO Market by API Potency / Containment Class -
• Non-Potent / Standard (OEB 1–3)
• Potent (OEB 4)
• Highly Potent / HPAPI (OEB 5)
• Cytotoxic and Hormonal
Oral Solid Dosage CDMO Market by Therapeutic Area -
• Oncology
• Cardiovascular and Metabolic (including Oral GLP-1, Statins, Anti-Hypertensives)
• Central Nervous System (including Abuse-Deterrent Formulations)
• Anti-Infectives
• Respiratory
• Gastrointestinal
• Pain Management
• Other Therapeutic Areas
Oral Solid Dosage CDMO Market by Customer Type -
• Big Pharma (Top 20)
• Mid-Cap Pharma
• Specialty and Branded-Generic Pharma
• Emerging Biotech and Virtual Companies
• Generic Manufacturers
Oral Solid Dosage CDMO Market by Contract Structure -
• Fee-for-Service
• FTE-Based
• Milestone / Risk-Sharing
• Royalty and Profit-Sharing
Oral Solid Dosage CDMO Market by Development Phase -
• Pre-Clinical / Discovery Support
• Clinical Phase I
• Clinical Phase II
• Clinical Phase III
• Commercial Manufacturing
• Post-Approval Lifecycle Management
Oral Solid Dosage CDMO Market by Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Oral Solid Dosage CDMO Market Snapshot
Chapter 4. Global Oral Solid Dosage CDMO Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Market Trends
4.5. Regulatory & Quality Landscape
4.6. Porter’s Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ Mn), 2025–2035
4.8. Market Penetration & Growth Prospect Mapping (US$ Mn), 2026–2035
4.9. Competitive Landscape & Market Share Analysis, 2026
4.10. CDMO Outsourcing & Manufacturing Value Chain Analysis
Chapter 5. Market Segmentation 1: By Service Type
5.1. Market Share, 2025 & 2035
5.2. Market Size (US$ Mn), 2022–2035
5.2.1. Formulation Development
5.2.2. Process Development and Scale-Up
5.2.3. Clinical Trial Manufacturing (Phase I / II / III)
5.2.4. Commercial Manufacturing
5.2.5. Packaging, Serialization, and Labelling
5.2.6. Analytical, Stability, and QC Services
5.2.7. Regulatory and CMC Support
Chapter 6. Market Segmentation 2: By Dosage Form
6.1. Market Share, 2025 & 2035
6.2. Market Size (US$ Mn), 2022–2035
6.2.1. Immediate-Release Tablets
6.2.2. Modified-Release Tablets (SR / CR / DR / ER / Pulsatile)
6.2.3. Coated Tablets (Film, Sugar, Enteric)
6.2.4. Hard Capsules (Gelatin and HPMC)
6.2.5. Soft Gelatin Capsules
6.2.6. Orally Disintegrating Tablets (ODT)
6.2.7. Multiparticulates (Pellets, Beads, Mini-Tablets, MUPS)
6.2.8. Granules, Sachets, and Stick Packs
6.2.9. Powders for Oral Suspension
6.2.10. Chewables, Lozenges, and Effervescent Tablets
Chapter 7. Market Segmentation 3: By Manufacturing Technology
7.1. Market Share, 2025 & 2035
7.2. Market Size (US$ Mn), 2022–2035
7.2.1. Wet Granulation
7.2.2. Dry Granulation and Roller Compaction
7.2.3. Direct Compression
7.2.4. Hot Melt Extrusion
7.2.5. Spray Drying
7.2.6. Fluid Bed Processing and Coating
7.2.7. Compression and Film Coating
7.2.8. Encapsulation (Powder, Pellet, LFHC)
7.2.9. Continuous Manufacturing
7.2.10. 3D Printing
Chapter 8. Market Segmentation 4: By API Potency / Containment Class
8.1. Market Share, 2025 & 2035
8.2. Market Size (US$ Mn), 2022–2035
8.2.1. Non-Potent / Standard (OEB 1–3)
8.2.2. Potent (OEB 4)
8.2.3. Highly Potent / HPAPI (OEB 5)
8.2.4. Cytotoxic and Hormonal
Chapter 9. Market Segmentation 5: By Therapeutic Area
9.1. Market Share, 2025 & 2035
9.2. Market Size (US$ Mn), 2022–2035
9.2.1. Oncology
9.2.2. Cardiovascular and Metabolic (including Oral GLP-1, Statins, Anti-Hypertensives)
9.2.3. Central Nervous System (including Abuse-Deterrent Formulations)
9.2.4. Anti-Infectives
9.2.5. Respiratory
9.2.6. Gastrointestinal
9.2.7. Pain Management
9.2.8. Other Therapeutic Areas
Chapter 10. Market Segmentation 6: By Customer Type
10.1. Market Share, 2025 & 2035
10.2. Market Size (US$ Mn), 2022–2035
10.2.1. Big Pharma (Top 20)
10.2.2. Mid-Cap Pharma
10.2.3. Specialty and Branded-Generic Pharma
10.2.4. Emerging Biotech and Virtual Companies
10.2.5. Generic Manufacturers
Chapter 11. Market Segmentation 7: By Contract Structure
11.1. Market Share, 2025 & 2035
11.2. Market Size (US$ Mn), 2022–2035
11.2.1. Fee-for-Service
11.2.2. FTE-Based
11.2.3. Milestone / Risk-Sharing
11.2.4. Royalty and Profit-Sharing
Chapter 12. Market Segmentation 8: By Development Phase
12.1. Market Share, 2025 & 2035
12.2. Market Size (US$ Mn), 2022–2035
12.2.1. Pre-Clinical / Discovery Support
12.2.2. Clinical Phase I
12.2.3. Clinical Phase II
12.2.4. Clinical Phase III
12.2.5. Commercial Manufacturing
12.2.6. Post-Approval Lifecycle Management
Chapter 13. Regional Market Estimates & Trend Analysis
13.1. Global Market Regional Snapshot, 2025 & 2035
13.2. North America
13.2.1. Market Revenue by Country (U.S., Canada, Mexico), 2022–2035
13.2.2. North America Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Service Type, 2022–2035
13.2.3. North America Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Dosage Form, 2022–2035
13.2.4. North America Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Manufacturing Technology, 2022–2035
13.2.5. North America Oral Solid Dosage CDMO Market Revenue (US$ Mn) By API Potency / Containment Class, 2022–2035
13.2.6. North America Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Therapeutic Area, 2022–2035
13.2.7. North America Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Customer Type, 2022–2035
13.2.8. North America Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Contract Structure, 2022–2035
13.2.9. North America Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Development Phase, 2022–2035
13.3. Europe
13.3.1. Market Revenue by Country, 2022–2035
13.3.2. Europe Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Service Type, 2022–2035
13.3.3. Europe Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Dosage Form, 2022–2035
13.3.4. Europe Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Manufacturing Technology, 2022–2035
13.3.5. Europe Oral Solid Dosage CDMO Market Revenue (US$ Mn) By API Potency / Containment Class, 2022–2035
13.3.6. Europe Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Therapeutic Area, 2022–2035
13.3.7. Europe Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Customer Type, 2022–2035
13.3.8. Europe Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Contract Structure, 2022–2035
13.3.9. Europe Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Development Phase, 2022–2035
13.4. Asia Pacific
13.4.1. Market Revenue by Country, 2022–2035
13.4.2. Asia Pacific Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Service Type, 2022–2035
13.4.3. Asia Pacific Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Dosage Form, 2022–2035
13.4.4. Asia Pacific Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Manufacturing Technology, 2022–2035
13.4.5. Asia Pacific Oral Solid Dosage CDMO Market Revenue (US$ Mn) By API Potency / Containment Class, 2022–2035
13.4.6. Asia Pacific Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Therapeutic Area, 2022–2035
13.4.7. Asia Pacific Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Customer Type, 2022–2035
13.4.8. Asia Pacific Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Contract Structure, 2022–2035
13.4.9. Asia Pacific Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Development Phase, 2022–2035
13.5. Latin America
13.5.1. Market Revenue by Country, 2022–2035
13.5.2. Latin America Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Service Type, 2022–2035
13.5.3. Latin America Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Dosage Form, 2022–2035
13.5.4. Latin America Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Manufacturing Technology, 2022–2035
13.5.5. Latin America Oral Solid Dosage CDMO Market Revenue (US$ Mn) By API Potency / Containment Class, 2022–2035
13.5.6. Latin America Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Therapeutic Area, 2022–2035
13.5.7. Latin America Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Customer Type, 2022–2035
13.5.8. Latin America Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Contract Structure, 2022–2035
13.5.9. Latin America Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Development Phase, 2022–2035
13.6. Middle East & Africa
13.6.1. Market Revenue by Country, 2022–2035
13.6.2. Middle East & Africa Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Service Type, 2022–2035
13.6.3. Middle East & Africa Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Dosage Form, 2022–2035
13.6.4. Middle East & Africa Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Manufacturing Technology, 2022–2035
13.6.5. Middle East & Africa Oral Solid Dosage CDMO Market Revenue (US$ Mn) By API Potency / Containment Class, 2022–2035
13.6.6. Middle East & Africa Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Therapeutic Area, 2022–2035
13.6.7. Middle East & Africa Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Customer Type, 2022–2035
13.6.8. Middle East & Africa Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Contract Structure, 2022–2035
13.6.9. Middle East & Africa Oral Solid Dosage CDMO Market Revenue (US$ Mn) By Development Phase, 2022–2035
Chapter 14. Competitive Landscape
14.1. Key Strategic Developments (Mergers & Acquisitions, Partnerships, Product Launches)
14.2. Market Share Analysis, 2026
14.3. Company Profiles (29 Players)
14.3.1. Catalent, Inc. (Novo Holdings)
14.3.2. Lonza Group AG (Capsugel Division)
14.3.3. Thermo Fisher Scientific / Patheon Pharma Services
14.3.4. Recipharm AB
14.3.5. Piramal Pharma Solutions
14.3.6. Boehringer Ingelheim BioXcellence
14.3.7. Aenova Group
14.3.8. Siegfried Holding AG
14.3.9. CordenPharma International
14.3.10. Hovione
14.3.11. Almac Group
14.3.12. Rottendorf Pharma
14.3.13. Delpharm
14.3.14. Famar Group
14.3.15. Quotient Sciences
14.3.16. Sterling Pharma Solutions
14.3.17. Adare Pharma Solutions
14.3.18. PCI Pharma Services
14.3.19. Cambrex Corporation
14.3.20. Alcami Corporation
14.3.21. UPM Pharmaceuticals
14.3.22. Pharmaceutics International, Inc.
14.3.23. AbbVie Contract Manufacturing
14.3.24. Bora Pharmaceuticals (Taiwan)
14.3.25. Jubilant Pharmova Limited
14.3.26. Granules India Limited
14.3.27. WuXi STA (a WuXi AppTec company)
14.3.28. Samsung Biologics (OSD Entry)
14.3.29. Dr. Reddy's Contract Pharmaceutical Services (CPS)
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Oral Solid Dosage CDMO Market is estimated to grow at a 7.0% CAGR during the forecast period for 2026 to 2035.
Catalent, Inc. (Novo Holdings), Lonza Group AG (Capsugel Division), Thermo Fisher Scientific / Patheon Pharma Services, Recipharm AB, Piramal Pharma Solutions, Boehringer Ingelheim BioXcellence, Aenova Group, Siegfried Holding AG, CordenPharma International, Hovione, Almac Group, Rottendorf Pharma
Oral Solid Dosage CDMO Market is segmented into Service Type, Dosage Form, Manufacturing Technology, API Potency / Containment Class, Therapeutic Area, Customer Type, Contract Structure, Development Phase and By Region
North America region is leading the Oral Solid Dosage CDMO Market.